Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
about
Cost-effectiveness analysis of guidelines for antihypertensive care in FinlandIncreasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.Meditative therapies for reducing anxiety: a systematic review and meta-analysis of randomized controlled trialsEvidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Challenges and Successes in Dissemination of Evidence-Based Treatments for Posttraumatic Stress: Lessons Learned From Prolonged Exposure Therapy for PTSDPregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.A report on economic studies of Australian mental health issues.Cost-effectiveness of cognitive-behavioural therapy for mental disorders: implications for public health care funding policy in Canada.Experience base and system context in mental health care reformReligion and anxiety treatments in primary care patients.The global burden of anxiety disorders in 2010.Community-based implementation of trauma-focused interventions for youth: Economic impact of the learning collaborative model.The Effects of Waiting for Treatment: A Meta-Analysis of Waitlist Control Groups in Randomized Controlled Trials for Social Anxiety Disorder.Cognitive Processing Therapy for Spanish-speaking Latinos: A Formative Study of a Model-Driven Cultural Adaptation of the Manual to Enhance Implementation in a Usual Care Setting.Associations between social anxiety and emotional intelligence within clinically depressed patients.Cost-effectiveness and long-term effectiveness of internet-based cognitive behaviour therapy for severe health anxiety.Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.Shyness programme: longer term benefits, cost-effectiveness, and acceptability.Effects of a transdiagnostic unguided Internet intervention ('velibra') for anxiety disorders in primary care: results of a randomized controlled trial.Who treats whom? An application of the Pathways to Care model in Australia.Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs.Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.What is the value of treating schizophrenia?Disability, employment and work performance among people with ICD-10 anxiety disorders.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.Disability, Employment and Work Performance Among People with ICD-10 Anxiety DisordersSocial Anxiety Disorder: Recent Developments in Psychological Approaches to Conceptualization and Treatment
P2860
Q33303769-DFDFEB98-F439-4709-BD9A-A74941574429Q33701842-1F9B510E-520F-4712-938D-D202E5800BCAQ34281715-B4D3301D-25BF-4E9E-B260-3050F1F8A953Q34465555-8984D70A-5CAE-4560-8C26-33016C212DF8Q35113914-CCDA61F1-0114-473C-B094-81A911FC722AQ36062003-15977EDA-7A45-4517-9C7F-DF339E7216F5Q36492427-9048F535-6A54-4F61-9A9F-1579CFE3A01FQ36628475-E46DD79E-861D-4531-945A-A80B5D0084C5Q36690985-756A050E-9778-4435-AE4A-79319C07098FQ36751629-0F8913B1-C780-41DB-A779-D26D601F6C2BQ38180929-027C4A98-7112-4B6B-B7A4-00025BBBCD5CQ38992375-5ABF797F-E7E0-470A-8060-097D9A290A7DQ39573343-70584484-5A3E-426C-967B-189337237BEDQ39632352-1CE5B9DD-A3C0-49F6-9D89-3FAF03A033A7Q44312017-3E02B0B9-42F2-469E-AFF8-8235BE8FF28DQ44983891-F17EB232-A05C-4D00-B719-DC23A3E0C3C2Q45009855-1FD93C2A-A109-4E83-BC7C-D2A5124FE904Q46810440-FEA4DB38-A715-49E7-A116-6EEDC11A82CEQ48040709-66EAC0D9-94FE-4B51-A978-219916A7A39BQ50118714-434B5A3B-6ED2-46D7-AFC6-D6092CE702CAQ50616231-7712C17D-29E7-42B9-ABE8-0D3D91305D34Q50738508-565EE8B1-4F46-4390-8E24-FE39995C7418Q50791201-C4CE119B-EB81-42C4-8D0A-337849DF8A95Q51933904-AA5E1E27-85AC-468F-B16B-225D32AF3BBAQ53091817-3A1A6DDA-2C39-4071-8B80-145DE3041416Q57149248-42D5FE87-068E-452B-B5C7-7AF8E845B27CQ59133033-B9C4F5CD-C279-4DF3-B90C-53A77D446139
P2860
Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Modelling the population cost- ...... eatment for anxiety disorders.
@en
Modelling the population cost- ...... eatment for anxiety disorders.
@nl
type
label
Modelling the population cost- ...... eatment for anxiety disorders.
@en
Modelling the population cost- ...... eatment for anxiety disorders.
@nl
prefLabel
Modelling the population cost- ...... eatment for anxiety disorders.
@en
Modelling the population cost- ...... eatment for anxiety disorders.
@nl
P2093
P1476
Modelling the population cost- ...... eatment for anxiety disorders.
@en
P2093
P356
10.1017/S003329170300881X
P407
P577
2004-01-01T00:00:00Z